ArticleJournal of molecular neuroscience : MN2026
Plasma CAF22 Predicts Incident Freezing of Gait in Parkinson's Disease: A Prospective Cohort Study.
Article in Journal of molecular neuroscience : MN, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Freezing of gait (FOG) is a disabling complication of Parkinson's disease (PD), but peripheral associations remain poorly defined. C-terminal agrin fragment-22 (CAF22) is a circulating biomarker of neuromuscular junction degradation. We investigated whether baseline plasma CAF22 predicts the development of FOG in PD patients. In this prospective cohort study, 233 patients with idiopathic PD and no baseline FOG were followed for 24 months with assessments at 6-month intervals. Incident FOG was identified using the New Freezing of Gait Questionnaire. Cox proportional hazards models assessed associations between CAF22 and time to first FOG, adjusting for age, sex, disease duration, motor severity, gait speed, muscle strength, cognitive performance, and levodopa-equivalent daily dose. During follow-up, 55 participants (23.6%) developed incident FOG. Higher baseline plasma CAF22 was associated with an increased risk of FOG per standard deviation increase (HR 1.4, 95% CI 1.09-1.81). This association remained significant after multivariate adjustment (adjusted HR 1.37, 95% CI 1.03-1.82). Baseline CAF22 concentrations were higher in participants with greater motor severity and slower gait speed, but showed weaker associations with global cognitive performance. Faster gait speed was independently protective against FOG (HR 0.64, 95% CI 0.52-0.78). Kaplan-Meier analyses demonstrated progressively lower FOG-free survival across increasing CAF22 tertiles (log-rank p = 0.046). Elevated baseline plasma CAF22 independently predicts incident FOG in PD. CAF22 may reflect peripheral neuromuscular dysfunction and could serve as a biomarker of FOG risk.
Indexed as
Identifiers
42557480What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.